Comparison of the Vela Dx Sentosa and in-house MiSeq Next-Generation Sequencing Systems for HIV-1 DNA Genotypic Resistance

European Meeting on HIV & Hepatitis 2020

Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays

European Meeting on HIV & Hepatitis 2020

Exploratory evaluation for the optimization of next generation sequencing HIV-1 drug resistance outcomes based on an in-house RNA extraction protocol

European Meeting on HIV & Hepatitis 2020

Associations between vitamin D and fibrosis, genotype, viral load in patients having chronic hepatitis C

European Meeting on HIV & Hepatitis 2020

Overview of the national hepatitis B viral load testing programe in Uganda

European Meeting on HIV & Hepatitis 2020

Comparison of the new Alinity m system with the established Abbott RealTime and Hologic Aptima Quant Assay in HIV-1, HCV and HBV viral load measurement including performance and turn-around times

European Meeting on HIV & Hepatitis 2020

The Significance of M2BPGi Marker and CCC DNA in Unknown Etiology Hepatitis

European Meeting on HIV & Hepatitis 2020

A pan-genotypic nearly whole genome amplification approach of HCV by a simple two-step RT-PCR combined with parallel Oxford Nanopore and Illumina sequencing produce highly accurate long-range sequences

European Meeting on HIV & Hepatitis 2020

A hybrid sequencing approach for accurate minority detection and resolving haplotype information

European Meeting on HIV & Hepatitis 2020

The quantification of HBeAg levels differ among the different phases of HBV infection, and can predict therapeutic outcome in the setting of immunosuppression driven HBV reactivation.

European Meeting on HIV & Hepatitis 2020

The effectiveness of the application of serological tests and laboratory indicators as part of RITA for the detection of recent HIV infection

European Meeting on HIV & Hepatitis 2020

Combined use of high-sensitivity serological and virological HBV markers can make better in predicting the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-neg/anti-HBc-pos patients in the context of oncohematological diseases.

European Meeting on HIV & Hepatitis 2020

Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates

European Meeting on HIV & Hepatitis 2020

TDR surveillance and clinically relevant resistance in Spain: 2019 update

European Meeting on HIV & Hepatitis 2020

Prevalence of drug resistance mutations to rilpivirine and doravirine among NNRTI-experienced patients in Italy

European Meeting on HIV & Hepatitis 2020

HCV resistance associated variants following directly acting agent therapy failure- real life data from Poland

European Meeting on HIV & Hepatitis 2020

Absence of GS-6207 Phenotypic Resistance in HIV Gag Cleavage Site Mutants, Patient Isolates With Gag Polymorphisms, and Isolates With Resistance To Existing Drug Classes

European Meeting on HIV & Hepatitis 2020

Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance database

European Meeting on HIV & Hepatitis 2020

Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases.

European Meeting on HIV & Hepatitis 2020

Susceptibility to bNAbs of transmitted HIV variants among recent infections in France

European Meeting on HIV & Hepatitis 2020

Baseline Hepatitis C Virus NS5A Resistance-Associated Polymorphisms in Patients with and without HIV coinfection in Mexico

European Meeting on HIV & Hepatitis 2020

Substantial clustered transmission of the acute hepatitis C among HIV co-infected men-who-have-sex-with-men (MSM)

European Meeting on HIV & Hepatitis 2020

Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates

European Meeting on HIV & Hepatitis 2020

Antiretroviral resistance in patients with multiple treatment failure in a low-middle income setting

European Meeting on HIV & Hepatitis 2020